Trial Profile

A Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter Study to Evaluate the Effects of Sotagliflozin on Clinical Outcomes in Hemodynamically Stable Patients with Type 2 Diabetes POST Worsening Heart Failure

Status: Discontinued

Phase of Trial: Phase III

Latest Information Update: 18 Jul 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Sotagliflozin (Primary)
Indications Cardiovascular disorders; Heart failure; Type 2 diabetes mellitus
Focus Registrational; Therapeutic Use
Acronyms SOLOIST; SOLOIST-WHF
Sponsors Lexicon Pharmaceuticals

15 Jul 2024 Results assessing cost savings of Sotagliflozin published in the Lexicon Pharmaceuticals Media Release
30 Jun 2024 According to a Lexicon Pharmaceuticals media release, new analysis of the pivotal Phase 3 SOLOIST-WHF published the Journal of the American College of Cardiology: Heart Failure
18 Jun 2024 According to a Lexicon Pharmaceuticals media release, new analysis of the pivotal Phase 3 SOLOIST-WHF published in the Journal of Comparative Effectiveness Research.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com